At Comprehensive Hematology Oncology, our research team brings clinical trials closer to home, providing patients with access to promising therapies and carefully designed research studies alongside comprehensive cancer care.
Clinical trials play an important role in advancing the field of hematology and oncology. These research studies evaluate new approaches to screening, diagnosis, prevention, and treatment while helping physicians and researchers develop better options for patients.
At Comprehensive Hematology Oncology, we are proud to offer clinical research opportunities close to home. Our clinical trials give eligible patients access to approved and investigational therapies while contributing to the development of new standards of care.
Each clinical trial follows a carefully designed protocol with specific eligibility requirements and safety measures. Depending on the study, clinical trials may progress through several phases:
Phase I: Evaluates safety, determines appropriate dosage, and studies how the body responds to a new treatment.
Phase II: Continues to evaluate safety while examining whether the treatment may be effective against a specific cancer or condition.
Phase III: Compares a new treatment or treatment approach with the current standard of care in a larger group of patients.
Phase IV: Conducted after a treatment has been approved to continue monitoring its long-term safety and effectiveness.
Clinical trials are conducted according to established protocols designed to protect participants and ensure that research is carried out consistently. Before a study begins, the protocol is reviewed by an Institutional Review Board (IRB) to help protect the rights, safety, and well-being of participants.
COMPREHENSIVE HEMATOLOGY ONCOLOGY PATIENT
Have questions about clinical trials, eligibility, or currently enrolling studies? Our Clinical Research Team is here to provide more information and help you understand your options.
| Trial Name | Category | View More |
|---|---|---|
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01) | FIRST LINE LUNG CANCER | View More |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | FIRST LINE LUNG CANCER | View More |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | FIRST LINE LUNG CANCER | View More |
| Study of Olomorasib (LY3537982) in Combination with Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02) | FIRST LINE LUNG CANCER | View More |
| A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | SECOND-LINE LUNG CANCER | View More |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | SECOND-LINE LUNG CANCER | View More |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17) | SECOND-LINE LUNG CANCER | View More |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | BREAST CANCER | View More |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | BREAST CANCER | View More |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | BREAST CANCER | View More |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant Plus a CDK4/6 Inhibitor, in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | BREAST CANCER | View More |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | BREAST CANCER | View More |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) | HEAD AND NECK CANCER | View More |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | UROTHELIAL CANCER | View More |
| Study of STP938 in Advanced Solid Tumours | SOLID TUMORS | View More |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | SOLID TUMORS | View More |
| Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) | OBSERVATIONAL TRIALS | View More |
| Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers | OBSERVATIONAL TRIALS | View More |
| Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies | OBSERVATIONAL TRIALS | View More |
| Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study | OBSERVATIONAL TRIALS | View More |
| Trial Name | Category | Trial URL |
|---|---|---|
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01) | FIRST LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT06119581 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | FIRST LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT05899608 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | FIRST LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT06627647 |
| Study of Olomorasib (LY3537982) in Combination with Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02) | FIRST LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT06890598 |
| A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | SECOND-LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT06568939 |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | SECOND-LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT06472245 |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17) | SECOND-LINE LUNG CANCER | https://clinicaltrials.gov/study/NCT07291037 |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | BREAST CANCER | https://clinicaltrials.gov/study/NCT05952557 |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | BREAST CANCER | https://clinicaltrials.gov/study/NCT06797635 |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | BREAST CANCER | https://clinicaltrials.gov/study/NCT06312176 |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant Plus a CDK4/6 Inhibitor, in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | BREAST CANCER | https://clinicaltrials.gov/study/NCT06065748 |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | BREAST CANCER | https://clinicaltrials.gov/study/NCT06492616 |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) | HEAD AND NECK CANCER | https://clinicaltrials.gov/study/NCT06256588 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | UROTHELIAL CANCER | https://clinicaltrials.gov/study/NCT07129993 |
| Study of STP938 in Advanced Solid Tumours | SOLID TUMORS | https://clinicaltrials.gov/study/NCT06297525 |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | SOLID TUMORS | https://clinicaltrials.gov/study/NCT06253871 |
| Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) | OBSERVATIONAL TRIALS | https://clinicaltrials.gov/study/NCT06230185 |
| Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers | OBSERVATIONAL TRIALS | https://clinicaltrials.gov/study/NCT06605404 |
| Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies | OBSERVATIONAL TRIALS | https://clinicaltrials.gov/study/NCT06369441 |
| Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study | OBSERVATIONAL TRIALS | https://clinicaltrials.gov/study/NCT07124000 |
Clinical trials evaluate the safety and effectiveness of cancer treatments and drugs. They are essential for new or improved therapies to receive approval and become available to patients.
Our goal is to provide patients access to approved and exploratory therapies without the need for long-distance travel. While clinical trials may not be available for every condition, you can discuss your options with your doctor or call (727) 344-6569, ext. 1025, to speak with a member of our research team.
Clinical trials for new cancer treatments follow a structured series of phases. Each phase builds upon the previous one, ensuring that the treatment is safe and effective before advancing further.
Early Phases (Phase 1 & Phase 2):
Later Phase (Phase 3):
There are also less common phases:
Below is an overview of the most common trial phases:
Purpose:
Purpose:
Purpose:
Some clinical trials use a combined phase design (Phase 1/2 or Phase 2/3 trials) to streamline research. These studies allow for a seamless transition between phases, enabling faster results with fewer participants.
Clinical trials follow strict guidelines to evaluate treatments. These studies are conducted according to predefined protocols that outline the trial’s purpose, procedures, and conduct.
The protocol is developed by the study sponsor, which may be a pharmaceutical company, academic institution, or government agency. It details how the trial will be conducted and who is eligible to participate. All research centers involved must adhere to the same protocol. To protect patient rights and safety, the protocol is also reviewed by an Institutional Review Board (IRB).
Clinical trials are conducted to assess the effectiveness of new cancer treatments. Patients who participate in these trials may benefit in several ways:
While success is not guaranteed, clinical trials have led to some of the most effective cancer treatments available today.
The benefits and side effects of cancer treatments vary for each patient. To ensure patient safety, strict guidelines are in place for all clinical trials. The research team will discuss any known or potential risks before participation. During the informed consent process, participants receive detailed written information about the safeguards in place before starting any clinical trial therapy.
Before participating in a clinical trial, you will meet with the study coordinator and the physician overseeing your progress. They will provide a detailed explanation of the study, including potential risks and benefits, alternative options, study duration, required visits, and all necessary procedures, exams, and tests.
If you choose to participate, you must sign an Informed Consent Form, which outlines all aspects of the study and confirms your understanding. Participation is entirely voluntary, and you have the right to withdraw at any time.
The screening process involves a review of your medical history and current medications. You will undergo necessary exams, tests, and procedures based on the study requirements, as outlined in the initial interview and the Informed Consent Form.
Once all screening tests are completed, eligible participants will proceed with the study. However, some patients may not qualify, and if deemed ineligible, all study-related procedures will be discontinued.
If you qualify for the trial, you will be assigned study medication according to the schedule provided during your initial interview and outlined in the Informed Consent Form.
Throughout the study, your adherence to the medication regimen will be monitored. You will need to return all medication containers at each visit. Depending on the study, you may also be required to maintain a daily diary and undergo additional tests or procedures.
At the study’s conclusion, the study coordinator and physician will perform a final assessment, including a physical exam and collection of any remaining study supplies. They will provide follow-up recommendations if necessary. Additionally, you may be contacted about future studies that match your interests.
Participating in a clinical trial involves two types of costs: patient care costs and research costs.
These are the standard medical expenses associated with treating any patient, whether they are part of a clinical trial or receiving conventional treatment. They include:
These costs are typically covered by third-party health plans, such as Medicare or private insurance.
Research costs are specific to clinical trial participation and may include:
These expenses are generally covered by the trial’s sponsoring organization, such as a pharmaceutical company, academic institution, or government agency. Before enrolling in a trial, discuss the financial aspects with your physician and research coordinator.
For the latest information on Medicare coverage for clinical trials, visit www.cms.hhs.gov/ClinicalTrialPolicies to review the Medicare Clinical Trials Quick Reference Guide.
Medicare typically covers cancer treatment and diagnostic trials if:
If you are unsure whether a trial is covered by Medicare, consult your doctor. Other covered trials may be available, so it’s essential to evaluate all options before enrolling in an uncovered study.
Medicare continues to cover medical services that are normally included in its benefits, even if they are part of a clinical trial. These include:
Medicare generally does not cover:
Before joining a clinical trial, confirm which costs will be covered by Medicare, insurance, or the study sponsor to avoid unexpected expenses.